Menu Philippe sold $38K of SOPH
Menu Philippe (Chief Medical Officer) sold 5,000 shares of SOPHiA GENETICS SA (SOPH) at $7.52 on 2026-08-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and that it was executed under a 10b5-1 plan. This can marginally influence sentiment but does not provide new information about business performance or guidance.
Market read
Traders may note insider selling, but the 10b5-1 framing reduces interpretive weight and limits actionable impact.
What to watch
The filing does not state motivations, and the disclosed post-sale holdings (218,387 shares) do not imply a complete exit. Without additional context, the signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS, reported by its Chief Medical Officer.
Ticker impact
SOPHiA GENETICS CMO Menu Philippe sold 5,000 shares in an open-market transaction at $7.5159 on 2026-08-12 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.
Form 4 provides transaction details (size, price, 10b5-1 pre-arranged plan). The article contains no new operational, financial, or regulatory catalyst for SOPH beyond the sale itself.
Market effects
Minimal. Insider sale disclosures typically do not reset sector expectations without accompanying company-specific news.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than negative expectations.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider transaction disclosure.
- insiderMenu Philippe
Chief Medical Officer who sold 5,000 shares under a 10b5-1 plan.
